156 related articles for article (PubMed ID: 30942916)
1. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
2. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
4. An anthrax toxin variant with an improved activity in tumor targeting.
Wein AN; Peters DE; Valivullah Z; Hoover BJ; Tatineni A; Ma Q; Fattah R; Bugge TH; Leppla SH; Liu S
Sci Rep; 2015 Nov; 5():16267. PubMed ID: 26584669
[TBL] [Abstract][Full Text] [Related]
5. Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.
Phillips DD; Fattah RJ; Crown D; Zhang Y; Liu S; Moayeri M; Fischer ER; Hansen BT; Ghirlando R; Nestorovich EM; Wein AN; Simons L; Leppla SH; Leysath CE
J Biol Chem; 2013 Mar; 288(13):9058-65. PubMed ID: 23393143
[TBL] [Abstract][Full Text] [Related]
6. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
10. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.
Elvina Xavier MA; Liu S; Bugge TH; Torres JB; Mosley M; Hopkins SL; Allen PD; Berridge G; Vendrell I; Fischer R; Kersemans V; Smart S; Leppla SH; Cornelissen B
J Nucl Med; 2019 Oct; 60(10):1474-1482. PubMed ID: 30954944
[TBL] [Abstract][Full Text] [Related]
11. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells.
Mackowiak da Fonseca J; Mackowiak da Fonseca II; Nagamine MK; Massoco CO; Nishiya AT; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 32987941
[TBL] [Abstract][Full Text] [Related]
13. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Schafer JM; Peters DE; Morley T; Liu S; Molinolo AA; Leppla SH; Bugge TH
PLoS One; 2011; 6(5):e20532. PubMed ID: 21655226
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
15. Tumor Targeting and Drug Delivery by Anthrax Toxin.
Bachran C; Leppla SH
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376328
[TBL] [Abstract][Full Text] [Related]
16. Lethal factor of anthrax toxin binds monomeric form of protective antigen.
Chvyrkova I; Zhang XC; Terzyan S
Biochem Biophys Res Commun; 2007 Aug; 360(3):690-5. PubMed ID: 17617379
[TBL] [Abstract][Full Text] [Related]
17. Anthrax fusion protein therapy of cancer.
Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
Stiles L; Nelson DJ
J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
[TBL] [Abstract][Full Text] [Related]
19. Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
Rozanov DV; Golubkov VS; Strongin AY
Int J Biochem Cell Biol; 2005 Jan; 37(1):142-54. PubMed ID: 15381157
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.
Khandia R; Pattnaik B; Rajukumar K; Pateriya A; Bhatia S; Murugkar H; Prakash A; Pradhan HK; Dhama K; Munjal A; Joshi SK
Oncotarget; 2017 May; 8(22):35835-35847. PubMed ID: 28415766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
